Detalhe da pesquisa
1.
Leveraging G-CSF prescribing in the outpatient setting: considerations beyond clinical factors-a questionnaire study.
Support Care Cancer
; 32(6): 347, 2024 May 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38743147
2.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589218
3.
Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.
Breast Cancer Res Treat
; 192(2): 375-383, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994879
4.
BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial.
Qual Life Res
; 31(3): 723-732, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324138
5.
Creation of a tool to evaluate supportive care.
Palliat Support Care
; : 1-8, 2022 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35913037
6.
Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.
Br J Cancer
; 125(11): 1486-1493, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588616
7.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
N Engl J Med
; 375(8): 717-29, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27557300
8.
Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries.
Breast J
; 22(1): 96-100, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26511594
9.
Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach.
Health Res Policy Syst
; 13: 72, 2015 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26635108
10.
Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
Cancer Med
; 13(9): e7168, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38733172
11.
Assessing excellence in translational cancer research: a consensus based framework.
J Transl Med
; 11: 274, 2013 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24168073
12.
[The pathologist 2.0.] / L'anatomopathologiste 2.0.
Ann Pathol
; 37(5): 345-346, 2017 Oct.
Artigo
em Francês
| MEDLINE | ID: mdl-29037419
13.
Actual costs of cancer drugs in 15 European countries.
Lancet Oncol
; 17(1): 18-20, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26670093
14.
[Adapted physical activity and metastatic cancer: What needs and expectations?] / Activité Physique Adaptée et cancer métastatique : quels besoins et quelles attentes ?
Bull Cancer
; 109(12): 1287-1297, 2022 Dec.
Artigo
em Francês
| MEDLINE | ID: mdl-36273935
15.
Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration.
JMIR Cancer
; 7(1): e23927, 2021 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33749606
16.
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
Genome Med
; 13(1): 44, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722295
17.
Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.
Mol Oncol
; 15(5): 1277-1288, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33734563
18.
[Real-life study of 7-year survival in patients treated with trastuzumab for HER2+ early breast cancer]. / Étude en vie réelle de la survie à 7 ans des patientes traitées avec trastuzumab pour un cancer du sein précoce HER2.
Bull Cancer
; 107(7-8): 745-755, 2020.
Artigo
em Francês
| MEDLINE | ID: mdl-32532419
19.
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
J Clin Oncol
; 38(11): 1186-1197, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32083990
20.
[Management of side effects related to adjuvant hormone therapy in young women with breast cancer]. / Gestion des effets secondaires de l'hormonothérapie du cancer du sein chez la femme jeune.
Bull Cancer
; 106(12S1): S37-S42, 2019 Dec.
Artigo
em Francês
| MEDLINE | ID: mdl-32008736